← 홈

ADC · 폐암 (NSCLC)

112개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 112개
ADCBiologicstalePrECOG, LLC.Phase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 9.4%임상시험 1상태 DISCONTINUED
ADCBiologicstaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Furmonertinib, 1L)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Furmonertinib, 2L+)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleRegeneron PharmaceuticalsPhase 1

REGN5093-M114 (REGN5093-M114)

Advanced NSCLC · Advanced NSCLC

#AdvancedNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 DISCONTINUED
ADCBiologicstaleSutro Biopharma, Inc.Phase 1

STRO-004 (STRO-004)

Head and Neck Squamous Cell Carcinoma HNSCC; Non-Small Cell Lung Cancer NSCLC · Head and Neck Squamous Cell Carcinoma HN

#HeadandNeckSquamousCellCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleTubulis GmbHPhase 2

TUB-040 (TUB-040)

Ovarian Cancer; Non-small Cell Lung Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleExelixisPhase 1

XB002 (XB002)

Non Small Cell Lung Cancer; Cervical Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMersana TherapeuticsPhase 1

XMT-1522 (XMT-1522)

Advanced Breast Cancer; Advanced Nonsmall Cell Lung Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMediLink Therapeutics (Suzhou) …Phase 2

YL202 should be intravenously infused (YL202 should be intravenously infused)

NSCLC; Breast Cancer · NSCLC

#NSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleZymeworks BC Inc.Phase 1

ZW251 (ZW251)

Hepatocellular Carcinoma; Squamous Cell Non-Small Cell Lung Cancer · Hepatocellular Carcinoma

#HepatocellularCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

sac-TMT (sac-TMT)

Non-small Cell Lung Cancer; NSCLC · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleCancer Institute and Hospital, …Phase 2

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING

6 / 6 페이지

← 이전다음 →